Revolutionary, minimally invasive long-term cardiac support device and mitral valve repair technology.
A less invasive procedure, improved quality of life and reduced risk of complications. These are some of the advantages of Prof. Jan Solem’s invention - an entirely new approach to the support of the cardiac function in patients with severe heart failure. The technology is applicable to a growing worldwide demographic of more than one million heart failure patients.
Two-thirds of cardiac output is due to the up-and-down movement of the mitral valve plane. The Syntach CS Device restores impaired movement of the mitral valve and naturally supports the heart. It is a permanent, active implant that can be inserted using a minimally invasive technique. It is smaller than existing left ventricle assist devices (LVADs) and is therefore suitable for both men and women of all sizes.
Syntach´s products are being developed and have not yet been approved for clinical use.
Syntach AB in Lund, Sweden has been awarded € 2.5 million as a grant and part of blended finance of up to € 17,5 million from the European Innovation Council (EIC) to support the development of its unique minimally invasive cardiac support system
We are a rapidly expanding company and constantly looking for experienced, skilled and motivated personnel. If you are interested in joining our team please send your application to firstname.lastname@example.org.
Positions that will become available soon are HW engineer, SW engineer, Mechanical engineer, Chief of Production and Logistics.
Postal address: Box 4004, SE-227 21 Lund, Sweden
Visiting address: Traktorvägen 6C, SE-226 60 Lund, Sweden
+46 46 270 87 55